Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tigecycline (Tygacil®) cannot be endorsed for use within NHS Wales in children from the age of eight years for the treatment of the following infections: complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections; complicated intra-abdominal infections (cIAI). Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
| Medicine name | tigecycline (Tygacil®) | |
| Formulation | 50 mg powder for solution for infusion | |
| Reference number | 2799 | |
| Indication | For the treatment of the following infections: complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections; complicated intra-abdominal infections (cIAI). |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/10/2015 | |
| Date of issue | 13/10/2015 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||